SCHEMBL2751069

SCHEMBL2751069

COC(=O)Cn1cc(-c2cnc(N)c(-c3nc4ccccc4s3)c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.44
MAPK1 P28482 3/20 0.43
MGLL Q99685 1/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
IKBKE Q14164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750077 0.90 BTK (0.46) METMAPK1MGLLMAPTSMN1; SMN2
SCHEMBL2749424 0.89 MET (0.49) METMAPK1MGLLMAPTSMN1; SMN2
SCHEMBL2748900 0.88 MAPK1 (0.45) METMAPK1MGLLHDAC1HDAC2
SCHEMBL2749226 0.87 CCNC (0.47) METMAPK1MGLL
SCHEMBL2749337 0.86 BTK (0.47) METMAPK1MAPTTP53SMN1; SMN2
SCHEMBL2749686 0.86 MET (0.47) METMAPK1MGLLNPC1RAB9A
SCHEMBL2750278 0.86 MAPK1 (0.43) METMAPK1MGLLMAPTHDAC1
SCHEMBL2749325 0.84 MAPK1 (0.47) METMAPK1MAPTHDAC1HDAC2
SCHEMBL2748653 0.84 BTK (0.47) METMAPK1MGLLMAPTTP53
SCHEMBL2748423 0.83 MET (0.50) METMAPK1MAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MET 38/4885MAPK1 97/4885MGLL 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.